Risperdal Gets Approval For Adolescents; FDA Concerns Delay Zyprexa

Johnson & Johnson's Risperdal beat Lilly's Zyprexa as the first drug into the adolescent schizophrenia and bipolar I disorder market, with FDA approval for risperidone for the two indications Aug. 22